NewAmsterdam Pharma (NASDAQ:NAMSW) Shares Down 19.2% – Time to Sell?

NewAmsterdam Pharma (NASDAQ:NAMSW) shares were down 19.2% during mid-day trading on Tuesday . The company traded as low as $20.05 and last traded at $20.9810. Approximately 341 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 891 shares. The stock had previously closed at $25.97.

NewAmsterdam Pharma Trading Down 19.2%

The firm’s 50-day moving average price is $23.03 and its two-hundred day moving average price is $22.18.

Institutional Trading of NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. acquired a new position in NewAmsterdam Pharma (NASDAQ:NAMSW) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 15,708 shares of the company’s stock, valued at approximately $397,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.